STAAR Surgical’s Q3 2025: December China Shipment Delivers Margin Lift, While Net Income Dips Slightly

Ticker: STAA. In its third-quarter 2025 results, STAAR Surgical reports EPS of $0.18 on a per-share basis and adjusted EBITDA per share of $0.68, with net sales totaling $94.7 million—up 6.9% year over year. The release also notes a notable one-time timing effect courtesy of the December China Shipment, paid in full in Q3 2025, which helps explain a significant swing in gross margin and a backdrop for EPS consensus discussion and revenue forecast expectations moving forward.

Quarterly numbers and what moved the dial

STAAR’s third quarter shows a solid top line at $94.7 million, with a year-over-year rise of 6.9%. A substantial portion of that growth is tied to non-China regions, where net sales excluding China reached $38.9 million—an increase of 7.7% year over year. The company attributes much of the overall growth to the December China Shipment’s contribution, which was fully paid during the quarter under extended payment terms.

Gross margin expanded to 82.2% from 77.3% a year earlier. Management attributes this improvement to the timing of recognizing the cost of sales tied to the December China Shipment and to cost reductions implemented in the first quarter of 2025, which helped reduce period costs.

Net income came in at $8.9 million, or $0.18 per share, down from $10.0 million, or $0.20 per share in the prior-year period. On the upside, Adjusted EBITDA reached $34.6 million, or $0.68 per share, more than doubling the prior-year figure of $16.2 million, or $0.33 per share.

Key highlights and takeaways

Net sales of $94.7 million, up 6.9% year over year.
December 2024 ICL shipment contributed $25.9 million to net sales and was paid in full during Q3 2025 under extended terms.
Net sales excluding China: $38.9 million, up 7.7% year over year.
Gross margin 82.2% vs. 77.3% prior year, aided by sales mix timing and cost reductions.
Net income of $8.9 million ($0.18 per share) versus $10.0 million ($0.20 per share) year ago.
Adjusted EBITDA of $34.6 million ($0.68 per share), up from $16.2 million ($0.33 per share) year ago.

Outlook and what to watch (EPS consensus, revenue forecast)

The company does not present a formal revenue forecast in this release, which leaves analysts’ EPS consensus and revenue expectations unanchored for the near term. In terms of earnings discipline, the quarter shows an earnings-per-share result that declined modestly versus the prior year despite a meaningful EBITDA uplift, illustrating the classic margin-versus-net-income dynamic. Investors should monitor how management balances cost discipline, inventory management, and the timing of shipments—especially given the China-linked shipment that affected both revenue composition and margin timing.

The omission of explicit guidance means market expectations for the next quarter will hinge on whether the December China Shipment cadence repeats or if future shipments follow a more typical cadence. As a result, a future EPS consensus could hinge on how STAAR manages costs, absorbs distributor dynamics outside China, and sustains demand for the EVO family in a competitive global retina-care landscape.

What this portends for STAAR and its peers

The quarter underscores a familiar theme in specialty medical devices: revenue can bend with shipment timing and payment terms, even as underlying demand remains resilient. For STAAR, the December China Shipment story is a double-edged sword—delivering higher gross margins when recognized in full in the quarter while injecting revenue composition risk if future shipments slip or alter payment terms. The rapid jump in Adjusted EBITDA signals management’s ongoing focus on cost control and efficiency gains, which is particularly important for capital-light segments where unit economics can be sensitive to mix shifts.

Sector peers should watch how STAAR navigates China exposure, distributor dynamics in non-China regions, and the pace of cost reductions that translate into higher EBITDA margins. If STAAR’s cost-reduction program persists and if the company can sustain growth outside China without escalating working capital, the stock could plausibly re-rate on-margin expansion even if net income growth remains modest in the near term.

Conclusion: timing, margins, and the long game

The Q3 2025 results present a nuanced picture: revenue is growing, gross margins are expanding, and EBITDA is blazing a path to profitability beyond the top-line narrative. The absence of explicit revenue guidance makes this a data point more than a forecast, leaving the market to infer the trajectory from quarterly shipment timing and cost discipline. For STAA investors and peers, the takeaway is less about a dramatic earnings surprise and more about the durability of margins in the face of shipment timing and the ongoing quest to optimize cost structure without sacrificing growth.

In a world where a single December shipment can tilt margins, STAAR’s results feel like a reminder that in specialized medical devices, the math of the quarter often hinges on the timing of big-ticket shipments, payment terms, and the rhythm of outside-the-China demand. If this is the baseline for 2025, sector participants will be listening closely for signals of a sustainable revenue path and whether the company can convert high EBITDA into continued EPS growth in the quarters ahead.